Priti Patel - Feb 1, 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
Chief Medical Officer
Signature
/s/ Robert Ho, Attorney-in-Fact for Priti Patel
Stock symbol
NLTX
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 03:39 PM
Previous filing
Aug 5, 2021
Next filing
May 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Restricted Stock Units Award $0 +70K $0.00 70K Feb 1, 2022 Common Stock 70K $0.00 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney